Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
PLoS One. 2013 Apr 30;8(4):e62917. doi: 10.1371/journal.pone.0062917. Print 2013.
Pulmonary exacerbations (PEx), frequently associated with airway infection and inflammation, are the leading cause of morbidity in cystic fibrosis (CF). Molecular microbiologic approaches detect complex microbiota from CF airway samples taken during PEx. The relationship between airway microbiota, inflammation, and lung function during CF PEx is not well understood.
To determine the relationships between airway microbiota, inflammation, and lung function in CF subjects treated for PEx.
Expectorated sputum and blood were collected and lung function testing performed in CF subjects during early (0-3d.) and late treatment (>7d.) for PEx. Sputum was analyzed by culture, pyrosequencing of 16S rRNA amplicons, and quantitative PCR for total and specific bacteria. Sputum IL-8 and neutrophil elastase (NE); and circulating C-reactive protein (CRP) were measured.
Thirty-seven sputum samples were collected from 21 CF subjects. At early treatment, lower diversity was associated with high relative abundance (RA) of Pseudomonas (r = -0.67, p<0.001), decreased FEV(1%) predicted (r = 0.49, p = 0.03) and increased CRP (r = -0.58, p = 0.01). In contrast to Pseudomonas, obligate and facultative anaerobic genera were associated with less inflammation and higher FEV₁. With treatment, Pseudomonas RA and P. aeruginosa by qPCR decreased while anaerobic genera showed marked variability in response. Change in RA of Prevotella was associated with more variability in FEV₁ response to treatment than Pseudomonas or Staphylococcus.
Anaerobes identified from sputum by sequencing are associated with less inflammation and higher lung function compared to Pseudomonas at early exacerbation. CF PEx treatment results in variable changes of anaerobic genera suggesting the need for larger studies particularly of patients without traditional CF pathogens.
肺部恶化(PEx)常与气道感染和炎症有关,是囊性纤维化(CF)患者发病率的主要原因。分子微生物学方法可检测 CF 气道样本在 PEx 期间的复杂微生物群。气道微生物群、炎症和 CF PEx 期间的肺功能之间的关系尚未得到很好的理解。
确定 CF 患者在接受 PEx 治疗期间气道微生物群、炎症和肺功能之间的关系。
在 CF 患者接受 PEx 的早期(0-3 天)和晚期(>7 天)治疗期间采集了咳出的痰和血液,并进行了肺功能测试。通过培养、16S rRNA 扩增子的焦磷酸测序和总菌和特定细菌的定量 PCR 分析痰。测量了痰中的白细胞介素 8(IL-8)和中性粒细胞弹性蛋白酶(NE);以及循环 C 反应蛋白(CRP)。
从 21 名 CF 患者中收集了 37 份痰样本。在早期治疗时,较低的多样性与假单胞菌的高相对丰度(RA)相关(r=-0.67,p<0.001),FEV(1%)预测值降低(r=-0.49,p=0.03)和 CRP 升高(r=-0.58,p=0.01)。与假单胞菌相反,专性和兼性厌氧菌与炎症减少和 FEV₁升高有关。随着治疗的进行,假单胞菌的 RA 和通过 qPCR 测量的铜绿假单胞菌减少,而厌氧属的反应则表现出明显的可变性。普雷沃氏菌 RA 的变化与 FEV₁对治疗的反应的可变性比假单胞菌或葡萄球菌更大。
通过测序从痰中鉴定出的厌氧菌与早期恶化时的假单胞菌相比,与炎症减少和肺功能更高相关。CF PEx 治疗导致厌氧属的变化具有可变性,表明需要对没有传统 CF 病原体的患者进行更大的研究。